Welcome to our dedicated page for agilon health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
agilon health, inc. filings document the company’s value-based healthcare services business, governance matters, capital structure and operating results. Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, executive appointment and compensation arrangements, and material definitive agreements, including amendments to the company’s credit agreement.
Definitive proxy statements cover shareholder voting matters, board governance and executive compensation. The filing record also includes capital-structure disclosures, such as a certificate amendment related to a reverse stock split of common stock, along with risk-factor and material-event disclosures relevant to agilon’s physician-partnership model and payor contracting environment.
agilon health, inc. (AGL) reported an insider equity transaction by Chief Accounting Officer Timothy Gertsch. On 2026-08-16, 17 shares of common stock were withheld at $96.90 per share to satisfy income tax withholding obligations in connection with the net settlement of restricted stock units; this did not represent an open-market sale. Following this tax-withholding disposition, Gertsch directly held 14,152 shares of common stock, which includes restricted stock units.
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report beneficial ownership of agilon health, inc. common stock. They disclose beneficial ownership of 692,541 shares of common stock, representing 4.15% of the outstanding class as of the reporting date.
Both entities report no sole voting or dispositive power. They report shared voting power over 666,033 shares and shared dispositive power over 692,541 shares. The amendment indicates that their position is now at or below the 5% ownership reporting threshold. AQR Capital Management, LLC is stated to be a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule is filed jointly on behalf of both entities.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 651,825.59 shares of agilon health, inc. common stock, representing 3.9% of the class as of 06/30/2026. All reported shares are held with shared voting and shared dispositive power, with no sole voting or dispositive power. The filing is an amendment and confirms that Goldman Sachs & Co. LLC is the registered broker-dealer and investment adviser subsidiary through which the securities are held. The Goldman Sachs reporting units also disclaim beneficial ownership for certain client and fund-related holdings as described in the exhibits.
agilon health reported sharp improvement for the quarter ended June 30, 2026. Total revenues were $1.49 billion, up 7% from $1.39 billion a year earlier. Gross profit reached $107 million versus a gross loss of $52 million. Net income was $18 million, compared with a net loss of $104 million. Medical margin improved to $197 million from negative $53 million, and Adjusted EBITDA was $70 million versus negative $83 million.
Total members on the platform fell 10% year over year to 549,000, including 437,000 Medicare Advantage members and 112,000 ACO model beneficiaries. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $257 million and total debt was $32 million. For full‑year 2026, management raised guidance, now expecting total revenues of $5,775–$5,860 million, medical margin of $465–$505 million, and Adjusted EBITDA of $75–$95 million. Third‑quarter 2026 guidance calls for revenues of $1,445–$1,475 million, medical margin of $105–$115 million, and Adjusted EBITDA between negative $5 million and $5 million.
agilon health, inc. reports that Chief Legal Officer Denise Zamore had 37 shares of Common Stock withheld on 2026-08-01 to satisfy income tax withholding and remittance obligations related to net settlement of restricted stock units. This is characterized as a tax-withholding disposition and not a sale. Following this transaction, she directly holds 66,075 shares of Common Stock, including restricted stock units.
agilon health, inc. announced that Chief Technology Officer Girish Venkatachaliah will leave the company effective August 1, 2026. His departure is governed by a Severance Agreement and General Release that becomes effective eight days after he signs it.
Under this agreement, he is entitled to $766,063 in cash severance, paid in installments over twelve months after the separation date. He will also continue to vest, through April 30, 2027, in his 2025 transformation equity award and other outstanding time- and service-vesting restricted stock units scheduled to vest on or before that date, subject to any performance-based vesting conditions. Venkatachaliah is expected to enter a Consulting Agreement to provide transition consulting services from August 1, 2026 through December 31, 2026, for no consideration other than this continued equity vesting.
agilon health, inc. Chief Financial Officer Jeffrey A. Schwaneke reported a routine tax-related share disposition. On the reported date, 2,311 shares of Common Stock were withheld by the company to satisfy income tax withholding and remittance obligations tied to the net settlement of restricted stock units, and this was not an open-market sale. After this withholding, Schwaneke directly holds 138,031 shares of Common Stock, which the disclosure notes includes restricted stock units.
agilon health, inc. Chief Legal Officer Denise Zamore reported a small tax-related share disposition. On the reported date, 485 shares of common stock were withheld by the company to cover income tax obligations from the net settlement of restricted stock units, and this did not involve an open-market sale. After this withholding, she held 66,112 shares directly, including restricted stock units.
Wulf John William reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director John William Wulf received an equity award of 2,133 shares in the form of restricted stock units as compensation. These units vest in full on June 2, 2027, subject to his continued service as a director. After this grant, he beneficially owns 16,765 shares, including restricted stock units, reflecting a 1-for-25 reverse stock split of the company’s common stock that became effective on March 30, 2026.